EA201690926A1 - Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек - Google Patents

Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек

Info

Publication number
EA201690926A1
EA201690926A1 EA201690926A EA201690926A EA201690926A1 EA 201690926 A1 EA201690926 A1 EA 201690926A1 EA 201690926 A EA201690926 A EA 201690926A EA 201690926 A EA201690926 A EA 201690926A EA 201690926 A1 EA201690926 A1 EA 201690926A1
Authority
EA
Eurasian Patent Office
Prior art keywords
iron
increase
patients
iii
reduce
Prior art date
Application number
EA201690926A
Other languages
English (en)
Russian (ru)
Inventor
Энрике Порадосу
Рон Бентсур
Джеймс Ф. Оливьеро III
Original Assignee
Керикс Байофармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Керикс Байофармасьютикалз, Инк. filed Critical Керикс Байофармасьютикалз, Инк.
Publication of EA201690926A1 publication Critical patent/EA201690926A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EA201690926A 2013-11-04 2014-11-03 Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек EA201690926A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (1)

Publication Number Publication Date
EA201690926A1 true EA201690926A1 (ru) 2016-09-30

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690926A EA201690926A1 (ru) 2013-11-04 2014-11-03 Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек

Country Status (15)

Country Link
US (3) US20160256486A1 (cg-RX-API-DMAC7.html)
EP (2) EP3747432A1 (cg-RX-API-DMAC7.html)
JP (3) JP2016535780A (cg-RX-API-DMAC7.html)
KR (1) KR102392441B1 (cg-RX-API-DMAC7.html)
CN (1) CN105873583A (cg-RX-API-DMAC7.html)
AU (1) AU2014341975A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016009901A8 (cg-RX-API-DMAC7.html)
CA (1) CA2928200A1 (cg-RX-API-DMAC7.html)
EA (1) EA201690926A1 (cg-RX-API-DMAC7.html)
HK (1) HK1223031A1 (cg-RX-API-DMAC7.html)
IL (1) IL245317A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016005734A (cg-RX-API-DMAC7.html)
SG (1) SG11201603091QA (cg-RX-API-DMAC7.html)
TW (2) TWI744215B (cg-RX-API-DMAC7.html)
WO (1) WO2015066593A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101665968B1 (ko) 2009-07-21 2016-10-13 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
KR20210131457A (ko) 2013-06-05 2021-11-02 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
ES2787218T3 (es) 2014-12-10 2020-10-15 Tricida Inc Polímeros de unión de protones para la administración oral
EP3452028A4 (en) 2016-05-06 2020-04-15 Tricida Inc. COMPOSITIONS AND METHOD FOR TREATING ACID-BASED DISORDERS
SG11202003451UA (en) 2017-11-03 2020-05-28 Tricida Inc Compositions for and method of treating acid-base disorders
CA3117071A1 (en) 2018-10-29 2020-05-07 Pharmacosmos Holding A/S Treating iron deficiency with ferric carboxymaltose
CN114286682A (zh) * 2019-02-09 2022-04-05 法码科思莫斯控股有限公司 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁
CN117999069A (zh) * 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (cg-RX-API-DMAC7.html) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
HUE025264T2 (en) * 2005-08-18 2016-02-29 Panion & Bf Biotech Inc Pharmaceutical-grade ferric citrate for medical use
HUE028029T2 (en) * 2006-01-30 2016-11-28 Panion & Bf Biotech Inc Method of treating chronic kidney disease
KR20080106506A (ko) * 2006-01-30 2008-12-08 글로보아시아 엘엘씨 만성 신장병의 치료 방법
KR101665968B1 (ko) 2009-07-21 2016-10-13 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
WO2012006473A1 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
CN113244209A (zh) * 2012-06-21 2021-08-13 凯克斯生物制药公司 柠檬酸铁在治疗慢性肾脏疾病患者中的应用

Also Published As

Publication number Publication date
CA2928200A1 (en) 2015-05-07
TW201609088A (zh) 2016-03-16
BR112016009901A8 (pt) 2020-04-14
EP3065734A4 (en) 2017-05-17
US20190307791A1 (en) 2019-10-10
JP2021073230A (ja) 2021-05-13
IL245317A0 (en) 2016-06-30
WO2015066593A1 (en) 2015-05-07
JP2019206562A (ja) 2019-12-05
CN105873583A (zh) 2016-08-17
JP2016535780A (ja) 2016-11-17
KR20160096597A (ko) 2016-08-16
EP3747432A1 (en) 2020-12-09
TWI744215B (zh) 2021-11-01
HK1223031A1 (zh) 2017-07-21
MX2016005734A (es) 2016-11-08
SG11201603091QA (en) 2016-05-30
TW202203910A (zh) 2022-02-01
EP3065734A1 (en) 2016-09-14
AU2014341975A1 (en) 2016-05-19
US20160256486A1 (en) 2016-09-08
JP6828100B2 (ja) 2021-02-10
US20250360167A1 (en) 2025-11-27
KR102392441B1 (ko) 2022-05-02

Similar Documents

Publication Publication Date Title
EA201690926A1 (ru) Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек
MX2014015615A (es) Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica.
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201890278A1 (ru) Антитела к pd-l1
MX2019006259A (es) Transporte para atravesar la barrera hematoencefalica.
BR112015025955A2 (pt) tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
BR112017016952A2 (pt) terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
PH12015502275A1 (en) Therapuetic uses of empagliflozin
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
Chavez et al. New insights into the regulation of vascular permeability
MX2020011190A (es) Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension.
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
PE20141577A1 (es) Espray para heridas
EA201990403A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
WO2010119991A3 (en) Anti-hgf antibody combinational cancer therapies
PH12015502301A1 (en) Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
EA201891533A1 (ru) Способы и композиции для лечения синдрома хантера
RU2013155841A (ru) Способ ранней диагностики хронической болезни почек
UA62757U (ru) Способ прогнозирования адекватности программного гемодиализа у больных с хронической болезнью почек v стадии
EA201790790A1 (ru) Антитела человека против vegfr-2/kdr
RU2013110191A (ru) Способ определения предикторной значимости мозгового натрийуретического пептида у больных хронической болезнью почек, получающих терапию программным гемодиализом
Chalone T. RYTÖMAA
Sapate Dr. DY Patil Vidyapeeth